Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mustafa Dikilitas

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Cancer Research and Clinical Oncology|June 23, 2012
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancerRamazan Yildiz, Mustafa Benekli, Metin Ozkan, et al.
Journal of Hematology & Oncology|December 7, 2025
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapyYi-Long Wu, Lin Wu, Nan Bi, et al.
Journal of Gastrointestinal Cancer|July 10, 2020
Author Correction: Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded CriteriaVolkan Ince, Sami Akbulut, Emrah Otan, et al.
Journal of Gastrointestinal Cancer|June 11, 2020
Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded CriteriaVolkan Ince, Sami Akbulut, Emrah Otan, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Cancer Research and Clinical Oncology|June 23, 2012
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancerRamazan Yildiz, Mustafa Benekli, Metin Ozkan, et al.
Journal of Hematology & Oncology|December 7, 2025
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapyYi-Long Wu, Lin Wu, Nan Bi, et al.
Journal of Gastrointestinal Cancer|July 10, 2020
Author Correction: Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded CriteriaVolkan Ince, Sami Akbulut, Emrah Otan, et al.
Journal of Gastrointestinal Cancer|June 11, 2020
Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded CriteriaVolkan Ince, Sami Akbulut, Emrah Otan, et al.
Pageof 3